explore -WSS

explore

author：knowledge 2025-09-30 00:38:55 - browse：487

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Air quality improving but still lags in Black, Hispanic communities

WSS

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

First medicine developed to treat MASH expected to be approved soon

Medicare Advantage insurers pressure Biden for bigger payments

Bring on the sabbaticals for nurses

Readout Newsletter: Illumina, CRISPR, Regeneron

explore

explore

Gilead needs Arcellx more than ever

entertainment

Affirmative action in medical school literally saved lives

Texas board proposes rules on abortion law emergency exemption

Guidelines to prevent youth baseball injuries need more muscle

CRISPR technology availability, affordability needs to be expanded

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

After affirmative action ruling, medical educators look to 'holistic review'

The problem with charging patients to message their doctors

Moonlake's readout produced a cash windfall. Risks remain

Pfizer, Moderna say biotech, pharma drug development is a sprint

hotspot

Texas board proposes rules on abortion law emergency exemption

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Bring on the sabbaticals for nurses

The Readout: Amylyx, Alumis, and Lundbeck drug updates

The drug industry has found itself all alone in Washington

explore

knowledge

entertainment

entertainment